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Statistical Analysis of Clewell et al. PBPK Model of Trichloroethylene Kinetics
Frederic Yves Bois
Institut National de L'Environnement Industriel et des Risques, INERIS, Verneuil-en-Halatte, France
A physiologically based pharmacokinetic model for trichloroethylene (TCE) in rodents and humans
was calibrated with published toxicokinetic data sets. A Bayesian Statistical framework was used to
combine previous information about the model Parameters with the data likelihood, to yield
posterior parameter distributions. The use of the hierarchical Statistical model yielded estimates of
both variability between experimental groups and uncertainty in TCE toxicokinetics. After
adjustment of the model by Markov chain Monte Carlo sampling, estimates of variability for the
animal or human metabolic Parameters ranged from a factor of 1.5-2 (geometric Standard deviation
[GSD]). Uncertainty was of the same order äs variability for animals and higher than variability for
humans. The model was used to make posterior predictions for several measures of cancer risk.
These predictions were affected by both uncertainties and variability and exhibited GSDs ranging
from 2 to 6 in mice and rats and from 2 to 10 for humans. Key words: Bayesian, human, Markov
chain Monte Carlo, mouse, PBPK model, rat, TCE, toxicokinetics, tricholoroethylene, uncertainty
analysis. — Environ Health Perspect 108(suppl 21:307-316 (2000).
http://ehpnet1.niehs.nih.gov/docs/2000/suppl-2/307-316bois/abstract.html
The recent development of a comprehensive
physiologically bascd pharmacokinedc (PBPK)
model of trichloroethylene (TCE) disposition
and metabolism in mice, rats, and humans (/)
offers us the opportunity to examine issues of
variability and uncertainty for diät solvent. In
particular, uncertainties in predicrion of vari-
ous cancer dose merrics deserve to be com-
puted, since they could be directiy used äs
input for improved risk assessments.
PBPK modeling provides a strong mecha-
nistic basis for predicrion of disposition and
metabolism of toxicanis. Yer much uneasiness
remains with the use of these modeis in toxi-
cology (2). Similarly, äs discussed in a recent
review and an accompanying commentary,
PBPK modeling has not seen the develop-
ment it promised for therapeuric compounds
(3,4). The reason for this essenrially lies in
the lack of Statistical merhods for calibraring
these modeis. Because ofindividual variability
and uncertainty, many parameters are diffi-
cult to measure accurately even for inbred
animal strains. Using input parameters or
presenting results in the form ofa single value
can therefore be very misleading (5). In the
absence of rigorous Statistical treatment,
inference presenred by PBPK modeling is
largely empirical, hypotheses are left unvali-
daced, and predictions lack realisric measures
of uncerrainry. This srate ofaffairs is unform-
nate, when considering the consequences (for
public health and national weifare) of the
decisions made using these modeis.
Obviously, correct Statistical treatment of
PBPK modeis is difficult, since these are large
nonlinear modeis with relatively small data
sets and a high degree of uncertainty and bio-
logical variability (6). It is also essential to
respect the fundamental specificity of PBPK
modeis, i.e., their high prior information
conrent, which they provide through the
opportunity ro use physiological information
on parameter values. Yet, although several
parameters have physiological meaning and a
narrow ränge ofpossible values, others—often
specific of the compound studied—lack such
definition and need to be identified by the fit-
ting of the model to concentration—time pro-
files. Final ly, most of the time, prior
physiological information is simply about
population averages and is not directiy
applicable to any particular individual for
which data were obtained. Fortunately, all
these problems can be solved in a unified way
though a Bayesian population toxicokinetic
approach, which is worth implemenring even
in the case of small numbers of study sub-
jects (7-10). Bayesian staristics provides a
natural way of merging a priori knowledge
gained by implemenring a physiological
model, with the in vivo experimental data. A
Bayesian numerical treatment can also deal
efficiently with the multilevel error strucrure
of pharmacokinet ic data ( 1 1 ) . This is
achieved through the use of an explicit sraris-
rical model, describing the links between the
various sources ofvariance (e.g., measure-
ment errors, popularion variability) present
in the data, in which the physiological model
is imbedded äs a determinisric component.
These techniques are demonscrated here in
the case ofTCE PBPK modeling.
Methods
Data
Mice. Similar to the study of Clewell et al.
( l ) , data from six published repons were used.
From the reported experiments, a total of 33
groups of animals were defined. Fisher and
Allen (12) exposed groups o f3o r4 male and
fcmale B6C3F] mice each (body weight [bw]
30 g), by gavage to TCE at concentradons of
487, 973, and 1,947 mg/kg (males, groups
1-3; females, groups 4-6, respectively).
Trichloroacetic acid (TCA) concentrarions in
venous blood were measured at various rimes
in all groups, äs well äs the venous blood con-
centrarions ofTCE for dosing group 2.
Fisher et al, (13) exposed groups of 14
female B6C3Fi mice each (bw 26.5 g) by
Inhalation to TCE in a closed chamber of
9.1 L, at concentrarions of300, 700, 1,100,
3,700, and 7,000 ppm (groups 7-11) and
groups of 15 male mice (bw 31g) each to
1,020, 1,800, 3,800, 5,600, and 10,000 ppm
(groups 12-16). The concentrarion ofTCE
in the air chamber was measured. The same
study also exposed four groups of 3 or 4 male
B6C3Pi mice each to TCE (bw 31 g) for 4 hr
at concentrarions of 110, 297, 368, and
748 ppm (groups 17-20); four groups of3 or
4 female mice each ro TCE for 4 hr at con-
centrarions of42,236,368,and 889 ppm
(groups 21-24). The venous blood concen-
trarions of TCE and TCA were measured at
various rimes.
Larson and Bull (14) exposed groups of4
male B6C3F] mice each (average bw 27 g) by
gavage to TCA at concentrarions of 20 and
100 mg/kg (groups 25 and 26). The venous
blood concentrations of TCA and
dichloroaceric acid (DCA) were measured.
Given the analytical technique used, it is sus-
pecred that the DCA concentrarions may be
artifaccually high (15).
Larson and Bull (16) exposed groups of
5-6 male B6C3F] mice each (bw 26.4 g) by
gavage to TCE at concentrations of
15 mmol/kg (1972 mg/kg), 4.5 mmol/kg
(592 mg/kg), and 1.5 mmol/kg (197 mg/kg)
(groups 27-29). The venous blood concen-
trations of TCE, free trichloroethanol
(TCOH), and TCA were measured at various
rimes. The venous blood concentrarions of
DCA were also measured in mice for group
27. Here also the DCA concentrarions may
be arrifactually high.
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Prout et al. (17) exposed male mice of
unspecified strain, most likely B6C3F; (bw
29.5 g) by gavage to 1,000 mg/kg TCE
(group 30). The venous blood concentrarions
ofTCE. free TCOH, and TCA, äs well äs Ae
cumulated amount of TCE exhaled, were
measured ar various times.
Templin et al. (18) exposed groups
comprising 4 male B6C3F[ mice each (bw
27 g) to TCE at concentrations of
3.8 mmol/kg (500 mg/kg), 0.76 mmol/kg
(100 mg/kg), and 15 mmol/kg (1,972.5
mg/kg) (groups 31-33). The venous blood
concentrations of DCA were measured in all
groups. The venous blood concentrations of
TCE, free TCOH, and TCA were also mea-
sured at various times for group 31. The DCA
concentrations may be artifactually high.
Rats. Ten experimental groups of rats
were identified in a subset of the above-
described reports. Fisher et al. (13) exposed
groups comprising 6 female F344 rats each
(bw 186 g) by inhalarion to 600 ppm TCE
for 4 hr (group l). The venous blood concen-
trations of TCE and TCA were measured at
various times. Under similar conditions,
groups comprising 6 male F344 rats each (bw
236 g) were exposed to 529 and 505 ppm
TCE (groups 2 and 3). The venous blood
concentrations ofTCE were measured in
group 2; the venous blood concentrations of
TCA were measured in group 3.
Larson and Bull (14) exposed groups
comprising 4 male F344 rats each (bw 331 g)
by gavage to TCA at concentrations of 20 and
100 mg/kg (groups 4 and 5). The venous
blood concentrations of TCA and DCA were
measured. For die same reasons äs above, the
DCA concentrations may be artifactually high.
Larson and Bull (16) exposed groups
comprising 5 or 6 male Sprague-Dawley rats
each (bw 404 g) by gavage to TCE at concen-
trations of 1.5 mmol/kg (197 mg/kg),
4.5 mmol/kg (592 mg/kg), and 23 mmol/kg
(3,024 mg/kg) (groups 6-8). The venous
blood concentrations of TCE, free TCOH,
and TCA were measured at various times.
Prout et al. (17) exposed male rats of
unspecified sirain (bw 190 g) by gavage to
1,000 mg/kg TCE (group 9). The same
variables äs in mice were measured.
Templin et al. (19) exposed groups com-
prising 4 male F344 rats each (bw 275 g)
with 0.76 mmol/kg (100 mg/kg) TCE (group
10). The venous blood concentrations of
TCE, free TCOH, and TCA were measured.
Humans. A set of published human
volunteer experimenis was also analyzed.
Monster et al. (20) exposed volunteers (group
l—average weight, 69.8 kg; alveolar Ventila-
tion rate, 16.7 L/hr; fraction of weight äs fat,
15%) to 70 and 140 ppm TCE for 4 hr. The
exhaled air concentrations and venous blood
concentrations of TCE, venous blood
concentrations of free TCOH and TCA, and
the cumulated quanrity of TCA excreted in
urine were recorded. In 1979, Monster et al.
(21) reponed another set of experimenrs in
which a group of volunteers (group 2—aver-
age weight, 80.2 kg; alveolar Ventilation rate,
16.7 L/hr; fraction of weight äs fat, 15%)
were repeatedly exposed to 70 ppm TCE for
4 hr/day for 5 days. In addition to the vari-
ables measured in group l, the cumulated
quantky of trichloroethanol glucuronide
(TCOG) excreted in urine was recorded at
various times.
Müller et al. (22) exposed a group of
humans (group 3) to 100 ppm TCE for 6 hr.
The same variables äs for group 2 were fol-
lowed. Müller et al. (23) exposed a group of
volunteers (group 4) ro 50 ppm TCE for
6 hr/day for 5 days. The venous blood con-
centrations of free TCOH and TCA, and the
cumulated quantities of TCA and TCOG
excreted in urine were recorded. In the same
articie, Müller et al. report exposure of two
groups (5 and 6) of volunteers to 100 ppm
TCE for 6 hr. For group 5, the exhaled air
concentrations and venous blood concentra-
tions of TCE, and the venous blood concen-
trations of free TCOH and TCA were
measured. For group 6, only the venous
blood concentrations of free TCOH and
TCOG are reponed.
Finally, group 7 comprises volunteers that
Stewart et al. (24). exposed ro 198.3 ppm
TCE, 7 hr/day (with a 30 min break in the
middle) for 5 days. In this experiment, the
exhaled air concentrarion and venous blood
concentrations of TCE, and the cumulated
quantities of TCA and TCOG excreted in
urine were recorded.
Toxicokinetic and Stadsdcal Model
The description of the physiological model
used can be found in Clewell et al. (7). The
model equations were transcribed to a format
suitable for MCSim (25). Three modifica-
tions were made to the model: a) One com-
partment was added to describe closed-
chamber exposures of mice by Fisher et al.
(13). V) The volume of the poorly perfused
companment and c) the blood flow to the
richly perfused comparunent were computed
by difference at each Iteration so that the sum
of the organ volumes equaled 82% of the
body weight and the sum of organ flows
equaled cardiac outpur. Given this reparame-
terization, the model has a total of 55 inde-
pendent parameters. Only 45 of diese were
adjusted for mice and rats and 40 for humans
because there is no information in the above
described data about the remaining 10 or 15
parameters. Neither do diese 10 or 15 para-
meters influence the fit to the data.
The statistical model describing un-
certainries and variabiliries was constructed
using a hierarchical population approach
(10,26), äs illustratecl in Figure l. It has two
major components: the group level and the
species or population level. At the group level,
various concentrations or quantities (y) were
measured. The expected values of these mea-
suremenrs are a funcrion ( f ) of exposure level
(E), time (t), a set of physiological parameters
of unknown values (9), and a set of mea-
sured, covariate parameters ((p) such äs body
weight. E, t, 6, and (p are experiment specific.
All animal or human subjecis in an experi-
ment were supposed to have behaved simi-
larly from a toxicokinetic point of view. The
funcrion / is the pharmacokinetic model
described above. The concentrations or quan-
tities actually observed are also affecied by
measurement error and interindividual vari-
ability within the group. Since the data are
aggregated at the group level, it is not possible
to reliably disentangle the two sources ofvari-
ability. The corresponding errors were
assumed to be independent and log-normally
distributed, with mean zero and variance O2
(on the log scale). This corresponds to a pro-
portional error model commonly used in
pharmacokinetic modeling (10,26,27). The
variance vecror O2 had nine components for
mice (since nine dirferent variables were mea-
sured) and eight components for rats and
humans.
At the species level each component of the
9 parameter set was assumed to be distributed
log-normally, with species averages p and vari-
ances 2? (in log scale). Some a priori knowl-
edge of p and S2 is available in the form of
"Standard" values for sonne parameters.
Uncertainry in these averages and variances
Figure 1. Graph of the statistical model describing the
dependence relationships between several groups of
variables. Symbols are P, prior distributions; |i, mean
parameters for a species; 2?, variances of the species-
level parameters; E, exposure; t. experimental sampling
times; 9, unknown "average" physiological parameters
for the individuais of a group; 9, measured physiological
parameters; /, toxicokinetic model; y, experimental
data; o2, variance of the experimental measurements.
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• was acknowledged under ehe form of a priori
log-normal distriburions for ehe population
means p (with hyperparameters M and S) and
a Standard inverse gamma distribution, with
Parameters a =1 and ß = £2 for the popu-
lation variances Z2 (see section below on
a priori parameter values).
Three types ofnodes are featured in
Figure l:
• Square nodes represent variables for
which the values were observed, such äs y
or <p; were fixed by the experimenters,
such äs E and t; or were fixed by our-
selves, such äs the prior on p and Z2.
• Circle nodes represent unknown variables,
such äs O2, 9, p, or Z2.
• The triangle represents the deierministic
physiological model /.
An arrow between two nodes indicates a
direct statistical dependence between the
variables ofthose nodes.
Prior Parameter Distriburions
A major advantage of physiological modeling
is to provide a priori information on several
of the mean parameter values for a species, äs
well äs some idea of the variability of the
parameters across individuais. Values for the
hyperparameters M were set on the basis of
the parameter values used by Clewell et al.
(7). For VMTC and KMT (the Michaelis-
Menten parameters for the formation of
DCA from TCA) Clewell et al. assumed null
values for mice and humans. A low value,
with large uncertainty, was assumed here. To
speciry S, the vector of a priori uncertainty
(Standard deviarions [SDs]) on the average
parameter values, a disrincrion can be made
between the physiological parameters or par-
tition coefficients (which are quite well
known) and the other merabolic or pharma-
cokineric parameters (which are model spe-
cific and little known a priori). For the first
group of parameters, values of S correspond-
ing to coefficients of Variation (CVs) of
20-50% were assigned (8-10). An exception
is the volume of the tracheobronchial com-
partment, quite uncerrain and for which S
was set to correspond to 200% CV. For the
second group of parameters, a "vague" distri-
bution was assumed and S was set to corre-
spond to 200% CV (quite uncertain) or
500% CV (very uncertain). For those para-
meters "the data were left to speak," All priors
on p were truncared (o ±2 X S or ±1.5 X S to
avoid reaching unrealistic values. The prior
SD, 2o, on group variability, was'set to 0.47
(corresponding to a CV of 50%) for all para-
meters. The square of that value was used äs
parameter ß in the inverse-gamma distribu-
tion, a default choice for variance compo-
nents in normal modeis (28), togecher with a,
a of l, giving a vague shape to chis prior.
Table l gives the values of exp(M)—i.e. the
geometnc mcan-
the natural scale.
-and exp(S), which lie on
The Standard no-informative prior distrib-
n/ _ 1 - ")\ _ _') - .')or2 x...x G„ • wasurion /'(Gi2,...,^2) .
used for O2. To avoid the risk of overparame-
terizarion (a perfect fit could be obcained for
some data sets, leading to implausible null esci-
mates of variance), diese variance components
were constrained to be larger than 0.29. That
value corresponds to a CV of approximarely
30%, a reasonable, minimal value for die com-




Information about the distribution o f a
group's 0 parameter values (which in this case
Table 1. Prior population geometric means, exp(M), and associated geometric Standard deviations, exp(S), for the

















































































































































































































































































Abbreviations: BW, body weight; duod., [luodenum; Ke, Elimination rate; K/, formation rate; K,,, Michaelis-Menten coefficient: ox.
oxidative metabolism; TB, tracheobronchiai; V^g^ maximal rate. ^caled parameter = scaling formula x scaling coefficient. Units:
weights in kg. flows in L/hr. volumes in L, kinetic parameters in mg/hr, mg/1. or hr' (;). For all parameters the scaling coefficients
were assumed to be log-normally distributed with truncations at 12 SDs except where indicated. 'Measured values given in the data
section were used when available. 'Truncation at -2 x SDs and +1.5 x SDs to respect summation constraints.
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are ehe parameters of interest) is given by ehe
experimental data and by the species parame-
ters. The species parameters are determined by
the 0 variables and their priors, which were
set. The variances CT2 are also estimated but are
of lesser importance to us (however, high pos-
terior variances may indicate a poor fit).
From Bayes' theorem, the joint posterior
distribution of the parameters to esrimate,
W, a2, p, ^ ly, (p, E, t. M, Z, Eo), is propor-
tional to the likelihood of the data multiplied
by the parameters' priors:
W^p^ly^E.t.M.S,!2)
- J\y\Q, a2, (p, E, t)']\6\ii, J?)'F(a2)
• ^pIM.S) • fl;2?122)
[l]
The likelihood term is given by the
normal measurement model:
log(J) - Mlog/(9, (p, E, t)G2), [2]
As mentioned above, the prior distribu-
tion for O2 is; P(aI2,...,0„2) - Gi~2 X ...
xo„-2.
The prior distribution of each component
of9 is an independent normal distribution:
[3]
with truncarion constraints.
Finally each component of p, or Z2 is
assigned an independent hyperprior distribu-
tion, \i - N(M,S2) and £2 - inverse-
gamma(2,£2), äs described above.
Current practice in Bayesian statisrics is to
summarize a complicated high-dimensional
poscerior distribution by random draws ofthe
vecror of parameters. This is currently the
most effecrive way ro perform high-dimen-
sional numerical Integration. Further simula-
tions can then be performed to compute,
under specified conditions, posterior distribu-
tions of quantities of interest, such äs various
measures more closelv related ro cancer risk
than exposure to TCE. Because there are
many parameters to esrimate, a combination
ofGibbs sampling and Metropolis-Hasring
sampling was used to perform a random walk
through the posterior distribution. These iter-
ative sampling procedures are parricularly
convenient in the case of hierarchical modeis.
They belong ro a class of Markov chain
Monte Carlo (MCMC) techniques that has
recently received much interest {10,29—34).
Three independent Markov chain Monte
Carlo runs were performed for each species.
Convergence was monitored using the
method ofGelman and Rubin (35).
Posterior Distribution ofPredicrions
The model was used to compute, a posteriori,
several Surrogate exposure metrics. For lung
tumors, the dose metrics proposed are the
lifetime average daily area under the chloral
concentrarion-time curve (LAD—AUC, in
mg-hr-L"1) in the tracheobronchial region,
and the maximal chloral concentration
achieved in the tracheobronchial region
(Oma'ln n^g'L"1); for kidney tumors, metrics
computed are the lifetime average daily
amount of cytotoxic metabolites (originaring
from dichlorovinylcysteine) generated by
gram of kidney (LAD-A, in mg-g~1); for liver
tumors, the LAD-A UC and C„ax ofTCA
and DCA are the proposed metrics.
To obtain the distribution of Surrogate
dose measures, several exposure scenarios
were simulated for each species (ei ther
.continuous exposure through Inhalation or
drinking water, Inhalation exposure 8 hr per
day, 5 days per week, inhalation exposure 7
hr per day, 5 days per week, or gavage once
per day, every day). A population of 1,000
individuais was simulated by sampling for
each one a random parameter vector from
N(p.,£), for a random set of the final esti-
mates of p and £. This sampling accounts for
covariance becween values of the population
parameters, since the l ,000 parameter sets are
random draws from their joint (mulrivariate)
distributions, not just from the marginal dis-
tributions. These simularions required sam-
pling several parameters that could not be
estimated wich the dara at hand. The sam-
pling distributions of these parameters (sum-
marized in Table 2) were defined on the basis
ofClewell et al. estimares ( l ) . In the absence
of relevant information, no covariance was
specified between those parameters.
Results
After a few thousand iterarions, the trajectory
of each parameter oscillates randomly around
a mean value, and these oscillations have sta-
bilized to a starionary regime. Remember that
the simularions converge ro a distribution,
not to a point. For mice and humans, 7,000
iterarions wert necessary to reach conver-
gence; for rats 12,000 had ro be performed.
One of every 5 of ehe last 5,000 simularions
of three independent Markov chains were
recorded, yielding 3,000 sets of parameter
values from which the inferences and predic-
rions presented in the following were made.
Quality of Data Adjustment
Figure 2 presents die data values predicted for
each species versus their observed counterparts



























































































'Scaled parameter = scaling fomiula x scaling coefficient. Units: weights in kg. flows in L/hr, volumes in L, kinetic parameters in
mg/hr. mg/L or hr11;). 'This parameter was sampled from W(0,1) with truncation [0. 2], to put high weight on zero or sinall values
while allowing fcf positive values.
11* i<r1 W 10' i(?
Observed Data Value
Figure 2. Predicted versus observed data values (all
concentrations or quantities) for the Monte Carlo itera-
tions of highest posterior probability. The outlying points
for humans are 2 points in Monster et al. [20,21} experi-
ments (see Figure 5) and misfitted points in Müller et al.
(22,23) experiments.
- 4 -
(all data values are concentrations). Predicrions
were made with ehe parameter set ofhighesc
posterior density. For a perfect fit, all points
would fall on the diagonal (equalky of pre-
dicred and observed values). Such an adjust-
ment is not expected given the analyrical
measurement errors in the data, but the devia-
dons are small and the fit seems overall reason-
able. The graph is presented on log-log scale,
since the errors are assumed to be lognormally
disu-ibuted and span a wide ränge. The residu-
ais are evenly spread along the diagonal, in par-
ticular for mice. For ratä, there seems to be one
ouclying point in the venous blood concentra-
tions offree TCOH, the model fitting well all
other data points in the same experiment. The
fit to human data leaves four groups of points
with high residuais. There seems ro be one
oudier in the TCA blood concentration data
of Monster et al. (21), and the last points are
very variable. More troublesome is the system-
aric underestimarion, by a factor of5, ofTCE
concentration in exhaled air during exposure
for the experiments of Muller et al. (22,23).
The posterior means of the intragroup
SDs 0 (representing measurement error and
intersubject variability) are mostly between
0.3 and 0.5 (corresponding to coefficients of
Variation ofabout 30-50%). Larger values are
found in mice for the venous blood concen-
tration ofTCE (ü = 0.55), caused by the
"noisy" data ofFisher and Allen (12) and of
Prout et al. (17), for the blood concentration
of DCA (ü = 0.60) due to the noise and
underprediction ofthe data (14,16,18}, and
for the blood concentration of free TCOH
(ü = 0.65) in the data of Prout et al. in which
various animals were observed at various
times. For rats, the blood concentration of
DCA (G = 1.14) seems to be systematically
underpredicted. For human;,, äs menrioned
above, the concentration of TCE in exhaled
air in the experiments of Müller et al. (22,23)
is systematically overesiimated and some
noise exists in the Siewart et al. (24) data.
This leads to high residual errors (G = 0.79).
Figure 3 presents the fit to the mouse data
of Fisher et al. (13). The residual error is
small, albeit with some degree of autocorrela-
tion. But, by their nature, these data are
prone to exhibiting such dependency of errors
and are quite difficult to model.
Fits to human data are crucial to risk
assessment and human toxicology of TCE.
Figures 4-7 show that very nice fits can be
obtained with the model to a ränge of data.
The model has been formally fitted and the
adjustments are systematically better than
those, already reasonable, obtained by Clewell
et al. (l). However, äs menrioned above, some
data remain poorly fitted. The model overesri-
mates exhaled air concentrations measured by
Müller et al., while underesrimaring part of
Figure 4. Maximum posterior probability fit of Monster
et al. {20,21} human data on TCE concentration in
exhaled air during and arter inhalation exposures. Dark
circles: repeated exposures to 70 ppm TCE; open circles:
4-hr exposures to 70 ppm TCE; crosses: 4-hr exposures
to 140 ppm TCE.
Figure 5. Maximum posterior probability fit of Monster
et al. [20.21) human data on TCA concentration in venous
blood during and after TCE inhalation exposures. Dark cir-
cles: repeated exposures to 70 ppm TCE: open circles:
4-hr exposures to 70 ppm TCE; crosses: 4-hr exposures to
140 ppm TCE. Note the dispersion of points at later times.
the TCE blood concentration data in the
decay portion. The two "misfits" are cenainly
related. However, me venous blood TCA and
TCOH concentrations fi-om the same experi-
ments are well fitted (data not shown). A simi-
lar Situation is observed in mice and rats, for
example, for the DCA data.
Posterior Parameter Distributions
The joint discriburion ofall parameters is
obtained in Output of the Markov chain
Monte Carlo simularions. This allows consid-
erarion ofmarginal distriburions (distriburions
of the parameters considered individually) but
also ofcorrelarions ofany Order. Table 3 sum-
marizes the distriburions of the species-level
parameter values obtained in the last 1,000
iterations of the three runs performed (results
of the three runs are pooled, and the distribu-
rions are established with 3,000 values). The
geometric means can be interpreted äs repre-
senting the values for an "average" mouse, rat,
or human. Note that the columns of geomet-
ric Standard deviarions (GSDs) represent
group variability among the species. Means
Figure 6. Maximum posterior probability fit of Monster
et al. [20,21) human data on cumulated TCA quantity
excreted in urine during and after TCE inhalation expo-
sures. Dark circles: repeated exposures to 70 ppm TCE;
open circles: 4-hr exposures to 70 ppm TCE.
Fignre 7. Maximum posterior probabitity fit of Monster
et al. (20,21) human data on total TCOH concentration in
venous blood during and after TCE inhalation exposures.
Dark circles: repeated exposures to 70 ppm TCE: open
circles: 4-hr exposures to 70 ppm TCE; crosses: 4-hr
exposures to 140 ppm TCE.
Figure 3. Evolution of TCE concentration in the exposure
chamber of groups of mice (13) äs a function of time. The
continuous lines show maximum posterior probability fits.
- 5 -
Table 3. Summary statistics of the species level (i.e., population) posterior parameter distributions for trichloro-

















































































































































































































































































































































Geo, geometric. "Geometrie mean and GSD are in parentheses and are given for each estimated population parameter. The GSD,
in that case, measures uncertainty in location or spread.
could be given for each animal or human
group defined in the data secrion above, buc
the tables are too large ro be presented here.
The following summarizes the informarion
the simulations give on the various strains or
individuais studied. Overall, the parameters
retain physiologically plausible values.
Mice. For mice the posterior mean values
for flows, volumes, and partition coefficients
and most metabolic paramerers are not very
different from their prior mean. However,
KM (oxidative affinity for TCE) is rwice äs
high äs a priori estimated. Noticeable differ-
ences are also found for KEHBC (biliary
excretion rate ofTCOG), which decreases by
a factor of 7, KEHRC (enteroheparic recircu-
lation rate ofTCOH), VMTC and KMT
(Michaelis-Menten parameters for the reduc-
rion ofreduction ofTCA to DCA), KUTC
(urinary excretion ofTCA), the last four
parameters being higher by a factor o f2 ,
KFC (production ofDCVC from TCE),
twice less important than a priori assumed,
VMTBC (V^ for TCE in Clara cells) is also
lower, but with a large uncertainty, and
finally KTSD (transport rate from stomach to
duodenum) posterior mean is somewhat
higher than its prior escimate. Uncenainties
(SDs) about all these geometric means ränge
from a few percencs (for physiological para-
meters) up to a facror of2 for son-ie metabolic
parameters. These uncertainties are usually
much lower than the prior uncertainties,
showing that subscantial informarion on
about all parameters has been gained from the
experimental data.
Variabilities, äs estimated by the inter-
group GSD (Table 3), ränge from 1.23,
which corresponds to a CV of about 20% for
some organ volumes, to 2.7 for KAD (intesri-
nai absorption rate, from duodenum ro liver).
Metabolic parameters have intergroup vari-
abilities of at least 1.34 (about 30% CV).
Differences between groups do not seem to
be caused by differing sexes or exposure lev-
els, äs no such pattern emerges from examina-
tion of group means. Strain cannot be a
factor, since only B6C3F; mice were studied.
Differences should therefore be ascribed to
interindividual variability or to differences
between laboratories (which could have unre-
ported experimental differences, such äs ani-
mal providers). Note that, a posteriori, there
does not seem to be a parricular problem with
the DCA measurements in Larson and Bull
(14,16) data (groups 25—29) or Templin
et al. (18) data (groups 31-33). The meta-
bolic parameters directiy related to DCA are
not systemarically different for these groups,
and the fits to the data are äs good äs
for other experiments. Only two DCA
concentrarion—time poinrs (at 0.25 hr) in
experiments 25 and 26 (14) may be too high
(the model underpredicts them by a factor of
2 or 2.5), but this may be simply due to noise
in the data.
Rats. For rats the posterior mean values
for most parameters are dose to their prior
mean. The largest differences are found for
the scaling coefficients of the volume of dis-
tribution ofTCOH (VDBWC, increased by
a factor of 1.4), and of DCA (VCDCAC,
decreased by a factor of 1.4), the fracrional
split ofTCE to TCA (PO) doubled, and the
enteroheparic recircularion of parameter of
TCOH (KHERC) tripled. SDs for these geo-
metric means reach a factor of 3 and tend to
be higher than those for mice (this can be
explained by the smaller rat data set).
Variabilities, äs estimated by the inter-
group GSD, also tend to be higher for rats:
they ränge from l .32 to 3.6 for KAD (duode-
num to liver absorption rate). Differences
between groups, most apparent for KAD, the
urinary excretion ofTCA (KUTC), and the
volume of distriburion ofTCA (VCTCAC),
cannot be ascribed to sex, strain, exposure
level, or laboratory, äs no parricular pattern
emerges from examinarion of group means.
Differences are therefore due to inter-
individual variability. Here also there does
not seem to be a parricular problem with
- 6 -
DCA measurements in groups 4 and 5 {14).
Metabolie parameters direcdy related to DCA
are not systematically different for these
groups, and die slight underpredicrions ofdie
model for early time points (at most 70%)
could be due to rneasurement uncertainiy.
Humans. The ratios of posrerior to prior
mean values for metabolic parameters in
humans ränge from a factor of 0.2 for
VMTC (the maximal rare of DCA formadon
from TCA) to a factor of6 for KEHBC (the
biliary excretion ofTCOG). The difference
for VMTC is actually a nice result; without
imposing a priori a null value to this parame-
ter, the resuking posterior is very low, indi-
cating that according to the human data very
little DCA is produced, even if this observa-
tion is indirect (i.e., this result is imposed by
the implicit mass balance of the other
metabolkes in humans). SDs for these geo-
metric means are also quite higher than for
animals, and reach a factor of3.2. This, äs for
rats, can be explained by the small human
data set.
Interestingly, variabilities for physiological
parameters are systematically higher than for
animals but about the same for metabolic
parameters. DifFerences between groups can-
not be ascribed to sex, since only males were
studied. They may be due to interindividual
variability. The subjects studied by Müller
et al. (22,23) have much higher blood over
air partition coefficients than subjects in other
studies. This is linked to the poor fit of the
model for the same subjects. The model can-
not accommodate the (apparently) differing
blood—air partition coefficient observed dur-
ing exposure and after exposure. This could
be linked to an experimental peculiarity in
exhaled air concentrarion measurements for
those studies.
Table 4 shows the highest covariances
between pairs of parameters for human group
a
VMOC
Figure 8. Correlation between the natural logarithms of
VMOC (l<n„ for oxidation of TCOH to TCA) and KMO
[corresponding («n,] tor human group 2 (21}}. The correla-
tion coefficient is 0.81 (see also Table 4).
2 (27). Similarly, high correlations are
obtained for every animal or human group.
These covariances can be up to 0.81 (between
VMOC and KMO, Figure 8) or even 0.94
(between the parameters VMRC and KMR).
Any Simulation neglecting to estimate these
covariances will produce incorrect predic-
tions, since these parameters cannot be sam-
pled independendy without producing highiy
improbable combinations and hence highiy
improbable predicrions.
Piedicdons of Cancer Dose Metrics
Additional subjects were simulated by
sampling parameier values from the esri-
mated population distributions summarized
in Table 3 and from the additional distribu-
tions given in Table 2. Sampling took inro
account paramecer covariance for the para-
meters listed in Table 3, since it was made
from l ,000 random samples of the MCMC
runs, at equilibrium. Remember that these
parameter sets are randomly drawn from
their joint (mulrivariate) distriburion not jim
from marginal distributions. Tables 5 to 8
summarize the posterior distributions of
LDA-AUC and C„„ for TCA and DCA in
liver for several exposure scenarios. The
results for lung, kidney were also computed
(data not shown). The 95% posterior confi-
dence intervals presented are defined äs the
inrerval between rhe 2.5th percentile and the
97.5th percentile. Figures 9 and 10 present
histograms of the posterior distributions of
TCA LDA-AUCand C„„, in the liver for
humans exposed continuously to l ppm
TCE. The impact of uncenainty and vari-
ability is large but not unrealisric; in these
extrapolations geometric SDs correspond to
facrors from l .8 to 9 (for chloral concencra-
tion in human lung when exposed through
drinking water). Except for one case, the val-
ues found by Clewell et al. (7) are all con-
tained within the 95% posterior confidence
intervais. The only area of disagreement is in
the mouse response to low-dose drinking
Table 4. Correlation coefficients among estimated model parameters for human group 2 (21). Parameter pairs for
which correlation coefficients were higher than 0.5 are in bold face.
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Table 5. Posterior disfribution summaries for the liver tumor dose metric LAD-AUC of TCA concentration in liver." All

































































































































"Inhalation exposures in ppm; oil gavage and drinking water exposure in mg/kg/day. 'Cl means confidence interval. 'Continuous expo-
sure. 'txposure 8 hr per day. 5 days per week. "Exposure 7 hr per day. 5 days per week. 'Gavage once per day, even/ day.
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Table 6. Posterior distribution summaries for the liver tumor dose metric Cmax of TCA concentration in liver.3 All


































































































































'Inhalation exposurss in ppm; oil gavage and drinking water exposure in mg/kg/day. ^ l means confidence interval. °Continuous expo-
sure. 'txposure 8 hr per day, 5 days par week. "Exposure 7 hr per day, 5 days per week. tavage once per day, every day.
Table 7. Posterior distribution summaries for the liver tumor dose metric L4D--4ÜCof DCA concentration in liver.3 All





























































































































'Inhalation exposures in ppm; oil gavage and drinking water exposure in mg/kg/day. 'Cl means confidence interval. 'Continuous expo-
sure. ''Exposure 8 hr per day, 5 days per week. "Exposure 7 hr per day, 5 days per week. tavage once per day, every day.
water administration of TCE, for which a
lower amount of TCA and a higher amounr
of DCA are predicted here, compared to
Clewell er al. esrimates.
Sensitivity ofDose Metrics to Modd
Parameters
Results of a stepwise multiple regression of
TCA LDA-AUC-with respect ro ehe model
parameters in the case ofhumans-continu-
ously exposed to l ppm TCE indicates that
many parameters condition the results (data
not shown). Among them figure key mera-
bolic constants but also physiological parame-
ters or partition coefficienis. The number of
parameters conditioning TCA LDA-AUC
explain the relatively large SDs for the risk
estimates presented in Table 5. The same
variables, in about the same order, influence
TCA C„^ (data not shown).
Discussion
Data
The grouping by studies is somewhat arbitrary
but was imposed on us by the aggregate
reporring of the data. It can still be jusrified,
since heterogeneity in batches of animals and
differences in laboratory procedures are
expected. As a consequence, all individuais
were supposed to behave similarly in a given
experiment. This is likely to lead to a moderate
underestimation of variability. Note also that
omer data sources could have been considered,
in particular for humans {36-43}, These addi-
tional data seis might be usefui for external
validarion ofthe model.
Method
. The proposed methodology is gaining interest
and is establishing itself for the calibrarion and
validarion ofPBPK modeis (8-10,44,45). A
Bayesian analysis allows us to combine rwo
fonns of informarion: a) prior knowledge from
the scientific licerature, and b) data from
Monster's experiments, in the context of the
physiological compartmental model. Neither
source of informarion is complete. If prior
knowledge were suffident, experiments would
not need to be performed, but data alone are
insufficient to pin down all parameters ro rea-
sonable values. Our goal was to fit the data
using scientifically plausible parameier values.
The posterior (i.e., after fitting) uncertainty for
such parameters is underesrimated if all physi-
ological parameters are considered perfectiy
known and sei to predefined values, a practice
too often adopted to alleviate computational
bürden. Prior uncenainry about physiological
parameter values needs to be taken into
account, unless it can be proven negligible by
sensitivity analysis of the posterior parameter
distriburions (not by sensitivity of the final
predicrions to be made). However, such a sen-
sitivity analysis of the fitting process itself, in
the case of PBPK modeis, is more difficult to
perform than simply considering all param-
eters uncertain. To obiain samples from the
joinr posterior distribution of all parameters,
MCMC sampling was used. Figure 11 is an
illustrarion of MCMC sampling compared to
simple Monte Carlo sampling. In the former,
the values drawn for each parameter start from
the prior distribution and converge, äs itera-
tions progress, to a data-adjusted, or updated,
posterior distribution. The posterior density
corresponds to the product ofthe prior density
by the data likelihood. In the case of simple
Monte Carlo sampling, all values are drawn
from the same distribution (equivalent to a
nonupdared prior). Beyond improving the fit,
the method used here also provides distribu-
tions of esrimates directiy usable äs inputs for
uncertainty analysis of cancer dose-response
relarionships. In addition, the posterior distrib-
utions of Table 3 can be taken äs new priors in
ftiture smdies. Finally, it can be checked a pos-
teriori that strong correlarions exist between
parameters (Table 4). A calibration neglecring
to estimaie and account for these covariances
would have produced incorrect estimates of
uncertainty, since these parameters cannot be
sampled independently without producing
highiy improbable combinarions of values and
hence highiy improbable predicrions. Another
sensitivity issue stems from the fact that
- 8 -
when good prior information is missing the
definition of some priors is vague and some-
whai arbkrary. Sensitivity analyses with respect
to those priors ideally should be performed.
However, in the context of a complex PBPK
model, such sensidvity analyses would involve
very heavy computarions.
Results
Interindividual human variability of TCE
metabolism, äs estimated here, is not very
large—GSDs of merabolic parameters ränge
from a facior of 1.5 to 2. However, only
small samples ofyoung Caucasian males were
analyzed. New data, developed by Dr.
Fisher's group, include females and allow an
assessment of potendal sex differences (46),
although animal data do not point to such
differences. Metabolism in animals appears äs
variable äs in young Caucasian males. SDs
corresponding to factors of 1.5-3 are to be
expected. It should also be noted that the
analysis does not a posteriori point to prob-
lems wich DCA concentrations in the Larson
and Bull (14,16) or Templin et al. (18)
experiments. There appears to be no conflict
between those data and others. The only
obvious misfit is in human exhaled air and
blood levels. Yet, it is present only for Müller
et al. (22,23) experiments and not for
Monster et al. (20,21) data. It is one of the
strengths of Bayesian PBPK modeling that
although the number of parameters is large,
overfitting is avoided and discrepancies in the
data are left apparent (47). Unfortunaiely
there is no obvious explanation for the
discrepancy. The new animal and human
data mentioned above may help us gain a bet-
ter understanding ofTCE inhaladon kinetics.
Despite the problem with Müller et al.
(22,23) data on exhaled air and blood
concentrations of TCE, those experiments
- 2 0 2 4 6
Natural Logarlthm öl TCA AUC-LAD in Human Liver
Figure 9. Posterior distribution histogram (n = 1,000) of
the natural logarithm of TCA LAD-AUC in human liver,
for a continuous 1-ppm inhalation exposure Isee Table
5). The spread of these model-predicted values is condi-
tioned by uncertainty and variability. The smooth line
represents the corresponding normal approximation
[geometric mean: log(88l = 4.48; GSD: log(2.5) = 0.92).
Table 8. Posterior distribution summaries for the liver tumor dose metric Cmas of DCA concentration in liver.3 All



























































































































Inhalation exposures in ppm; oii gavage and drinking water exposure in mg/kg/day. ^ l means confidence interval. "Continuous
exposure. ''Exposure 8 hr per day. 5 days per week. "Exposure 7 hr per day, 5 days per week. 'öavage once per day, every day.
were not discarded from the data set. The
model is not much affected by the misfit, and
metabolite levels are well predicted.
The posterior predictions for risk
measures are affected by expectedly large
uncertainries and some degree of variability.
Uncertaindes depend on species (condirioned
by the amount of data available for that
species), end points (still conditioned by the
data), or exposure levels and patterns (since
different parameters or combinations thereof
condition outcome in different siruations).
Variabllities seem to be of about the same
magnitude in small groups of humans and
animals. For the modeling of animal cancer
bioassay internal exposures or human popula-
tion exposures, the variability found here
- 2 0 2 4Cmax TCA liver human 1 ppm
Figure 10. Posterior distribution histogram (n= 1,000) of
the natural logarithm of TCA C^ax in human liver. for a
continuous 1-ppm inhalation exposure (see also Table
5). The spread of these model predicted values is condi-
tioned by uncertainty and variability. The smooth line
represents the corresponding normal approximation
(geometric mean: log(3.9) = 1.36; GSD: log(2.6) = 0.96).
would be damped by averaging effects.
Uncertainty would therefore dominate, and
variability could be neglected, in a first
approximation. This would require condi-
doning internal exposure esumates at various
dose levels on the same parameter vectors;
exposure groups would not be simulated
independently.
Finally, one of the challenges to modeling
in toxicology is the füll exploitarion of the
numerous data sets collected during epidemi-
ological or occupadonal hygiene studies, and
generally in settings where exposure levels are
unknown. Most of the rimes very simplisric
analyses of such data are performed because
200 400 600 800 1000
Iteration
Figure 11. Illustration of Markov chain Monte Carlo
(MCMC) sampling, compared to simple Monte Carlo
sampling. In MCMC sampling, the values drawn for a
Parameter 6 (circles) Start from the prior distribution and
converge, äs iterations progress, to a data-adjusted, or
updated, posterior distribution. The posterior density
corresponds to the product of the prior density by the
data likelihood. In the case of simple Monte Carlo sam-
pling (crosses), all values are drawn from the same dis-
tribution (equivalent to a nonupdated prior).
- 9 -
of l ack of experience in more powerfui
methodologies. There is no difficulty, in the
above statistical framework, in considering
exposure äs a paramcter or function to esri-
mate. A major problem, however, resides in
accounting fully for the uncertainties scem-
ming from unknown time-varying exposures.
The impact of pamcular functional forms for
the time evolution of exposure has not yet
been thoroughiy studied and validated. As
progress is made on such questions, toxico-
kineric modeling will become a more power-
fui and widespread tool for drug development
and toxicity assessment. A publidy accessible
database of individual animal and human
data on kinetics and metabolism ofmajor sol-
vents should be gathered and offered to pub-
lic access. This would allow a standardizarion
ofanalyses and their improvement.
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